Olema Pharmaceuticals, Inc. (OLMA) Fair Value 2026

OLMA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (34/100)

Quick Summary — As of 2026-08-28, Olema Pharmaceuticals, Inc. (OLMA) trades at $10.27. QOC: 5.1/10. Value Trap Risk: 34/100 (LOW). 1/13 models active.

Key Facts

Ticker
OLMA
Price
$10.27
Quality Score
5.1/10
Value Trap Risk
34/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give OLMA?

1 Intrinsic Value Models vs. Current Price ($10.27)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.27 -97.4%

All Models Active

All 1 models are displayed above.

What Is Olema Pharmaceuticals, Inc. (OLMA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Olema Pharmaceuticals, Inc.'s intrinsic value is estimated at $0.27, suggesting the stock is overvalued at its current price of $10.27. With 1 out of 1 models flagging downside (-97.4% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About OLMA?

1 of 13 models are currently active for OLMA. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does OLMA Rank in Biotechnology?

Among 625 Biotechnology stocks, OLMA ranks #291 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Olema Pharmaceuticals, Inc. competes in an environment where partnership revenue often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is OLMA a Value Trap?

CirclFi's Value Trap algorithm assigns OLMA a score of 34/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Olema Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Olema Pharmaceuticals, Inc. is rated at 5.1/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every OLMA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across OLMA's 1 active models, average confidence is 56%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Olema Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

IMVTImmunovant, Inc.QOC 5.1DYNDyne Therapeutics, Inc.QOC 5.1ORICORIC Pharmaceuticals, Inc.QOC 5.1KRROKorro Bio, Inc.QOC 5.1KAPAKairos Pharma, Ltd.QOC 5.1IMNMImmunome, Inc.QOC 5.1INOInovio Pharmaceuticals, Inc.QOC 4.5PHARPharming Group N.V.QOC 2.6STOKStoke Therapeutics, Inc.QOC 6.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: IMVT · DYN · ORIC · KRRO · KAPA · IMNM · INO · PHAR · STOK · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to OLMA?

6 companies across all industries closest to OLMA’s Quality of Company score of 5.1/10.

ARAIArrive AI Inc.QOC 5.1ACONAclarion, Inc.QOC 5.1AEROGrupo Aeromexico, S.A.B. de C.VQOC 5.1IMSRTerrestrial Energy Inc.QOC 5.1MACIMelar Acquisition Corp. IQOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ARAI · ACON · AERO · IMSR · MACI · NVDA

Where Does OLMA Sit in CirclFi's Biotechnology Rankings?

OLMA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Olema Pharmaceuticals, Inc.’s Valuation?

What is Olema Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Olema Pharmaceuticals, Inc. (OLMA). The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is OLMA overvalued or undervalued right now?

At $10.27, 0 of 1 active models suggest OLMA may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Olema Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.1 mean for OLMA?

Olema Pharmaceuticals, Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on OLMA?

CirclFi analyzes OLMA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is OLMA a value trap in 2026?

Olema Pharmaceuticals, Inc.'s Value Trap score is 34/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Olema Pharmaceuticals, Inc. (OLMA) a Quality of Company score of 5.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/OLMA/ · Methodology
Primary sources for this OLMA valuation
  • Financial statements: Olema Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001750284) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for OLMA as of ; valuations recomputed .